Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020533

« Back to Dashboard

NDA 020533 describes NAROPIN, which is a drug marketed by Fresenius Kabi Usa and is included in one NDA. It is available from four suppliers. There are four patents protecting this drug and three Paragraph IV challenges. Additional details are available on the NAROPIN profile page.

The generic ingredient in NAROPIN is ropivacaine hydrochloride. There are thirteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the ropivacaine hydrochloride profile page.

Summary for 020533

Tradename:	NAROPIN
Applicant:	Fresenius Kabi Usa
Ingredient:	ropivacaine hydrochloride
Patents:	4
Formulation / Manufacturing:	see details

Pharmacology for NDA: 020533

Ingredient-type	Amides
Physiological Effect	Local Anesthesia

Suppliers and Packaging for NDA: 020533

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
NAROPIN	ropivacaine hydrochloride	SOLUTION;INJECTION	020533	NDA	General Injectables & Vaccines, Inc	52584-286	N	52584-286-35
NAROPIN	ropivacaine hydrochloride	SOLUTION;INJECTION	020533	NDA	Fresenius Kabi USA, LLC	63323-285	N	63323-285-13

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;INJECTION			Strength	20MG/10ML (2MG/ML)
Approval Date:	May 1, 1998	TE:	AP	RLD:	Yes

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;INJECTION			Strength	40MG/20ML (2MG/ML)
Approval Date:	Sep 24, 1996	TE:	AP	RLD:	Yes

Profile for product number 003

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;INJECTION			Strength	100MG/20ML (5MG/ML)
Approval Date:	May 1, 1998	TE:	AP	RLD:	Yes

Expired US Patents for NDA 020533

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Fresenius Kabi Usa	NAROPIN	ropivacaine hydrochloride	SOLUTION;INJECTION	020533-001	May 1, 1998	➤ Try a Free Trial	➤ Try a Free Trial
Fresenius Kabi Usa	NAROPIN	ropivacaine hydrochloride	SOLUTION;INJECTION	020533-001	May 1, 1998	➤ Try a Free Trial	➤ Try a Free Trial
Fresenius Kabi Usa	NAROPIN	ropivacaine hydrochloride	SOLUTION;INJECTION	020533-003	May 1, 1998	➤ Try a Free Trial	➤ Try a Free Trial
Fresenius Kabi Usa	NAROPIN	ropivacaine hydrochloride	SOLUTION;INJECTION	020533-001	May 1, 1998	➤ Try a Free Trial	➤ Try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.